Incident atherosclerotic cardiovascular disease

1. Trimethylamine n-oxide has no effect on incident atherosclerotic cardiovascular disease in humans (No significant association: HR 1.03 (95% CI 0.85–1.25); P-trend=0.668).

   “but not normal or mildly reduced renal function (eGFR ≥60 mL/min per 1.73 m2: HR, 1.03 [95% CI, 0.85-1.25]; P-trend=0.668).”

   HumansNormal or mildly reduced renal function: eGFR ≥60 mL/min per 1.73 m2plasma

   Longitudinal Plasma Measures of Trimethylamine N-Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community-Based Older Adults

   Journal of the American Heart Association·16 Aug 2021

More on Trimethylamine n-oxide

1. Trimethylamine n-oxide is associated with incident atherosclerotic cardiovascular disease in humans (Highest versus lowest quintile HR 1.21 (95% CI 1.02–1.42); eGFR-adjusted HR 1.07 (95% CI 0.90–1.27)).

   “After multivariable adjustment, higher levels of TMAO were associated with a higher risk of incident ASCVD”

   HumansMultivariable-adjusted association; attenuated after adjustment for estimated glomerular filtration rateplasman = 4,131

   Longitudinal Plasma Measures of Trimethylamine N-Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community-Based Older Adults

   Journal of the American Heart Association·16 Aug 2021

More on Trimethylamine n-oxide